<DOC>
	<DOC>NCT01266499</DOC>
	<brief_summary>Klebsiella pneumonia, inhabitant of the digestive tract, is a frequent nosocomial pathogen. It is currently the fourth most common cause of pneumonia and fifth most common cause of bacteremia in intensive care patients (1-3). The aim of the present randomized controlled trial is to assess the efficacy of non-absorbable oral antibiotics in the eradication of the KPC carrier state.</brief_summary>
	<brief_title>A Study Evaluating the Role of Oral Antibiotics in an Aim to Eradicate Carrier State of Carbapenem- Resistant Klebsiella Pneumonia (KPC).</brief_title>
	<detailed_description />
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Bacteremia</mesh_term>
	<mesh_term>Klebsiella Infections</mesh_term>
	<mesh_term>Anti-Bacterial Agents</mesh_term>
	<mesh_term>Colistin</mesh_term>
	<mesh_term>Polymyxins</mesh_term>
	<mesh_term>Gentamicins</mesh_term>
	<criteria>Inclusion Criteria 1. Patient identified as a KPC carrier. 2. Patient capable to understand and sign informed consent 3. Age &gt; 18 4. Patient capable to receive oral medication 1. Patient unable to sign informed consent 2. Age â‰¤ 18 3. Pregnant/lactating female 4. Patient not expected to survive &gt; 2 weeks. 5. Patient unable or not allowed to receive oral medications 6. A known allergy to study drugs.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>Klebsiella , pneumonia, carbapenem-hydrolyzing lactamase, carbapenem-resistant Klebsiella (KPC), eradication,</keyword>
</DOC>